Corbus Pharmaceuticals Holdings Inc (CRBP)
38.77
+0.57
(+1.49%)
USD |
NASDAQ |
May 03, 16:00
38.81
+0.04
(+0.10%)
After-Hours: 20:00
Corbus Pharmaceuticals Holdings Enterprise Value: 402.67M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 402.67M |
| May 02, 2024 | 396.68M |
| May 01, 2024 | 386.70M |
| April 30, 2024 | 384.49M |
| April 29, 2024 | 369.78M |
| April 26, 2024 | 355.17M |
| April 25, 2024 | 347.29M |
| April 24, 2024 | 368.73M |
| April 23, 2024 | 391.84M |
| April 22, 2024 | 391.42M |
| April 19, 2024 | 407.61M |
| April 18, 2024 | 379.13M |
| April 17, 2024 | 385.75M |
| April 16, 2024 | 427.36M |
| April 15, 2024 | 444.17M |
| April 12, 2024 | 424.52M |
| April 11, 2024 | 415.59M |
| April 10, 2024 | 396.15M |
| April 09, 2024 | 389.01M |
| April 08, 2024 | 417.27M |
| April 05, 2024 | 415.28M |
| April 04, 2024 | 404.77M |
| April 03, 2024 | 399.83M |
| April 02, 2024 | 388.90M |
| April 01, 2024 | 394.47M |
| Date | Value |
|---|---|
| March 28, 2024 | 407.61M |
| March 27, 2024 | 369.04M |
| March 26, 2024 | 375.14M |
| March 25, 2024 | 369.67M |
| March 22, 2024 | 362.42M |
| March 21, 2024 | 395.61M |
| March 20, 2024 | 406.32M |
| March 19, 2024 | 443.99M |
| March 18, 2024 | 432.03M |
| March 15, 2024 | 453.64M |
| March 14, 2024 | 468.86M |
| March 13, 2024 | 489.32M |
| March 12, 2024 | 463.09M |
| March 11, 2024 | 396.98M |
| March 08, 2024 | 466.76M |
| March 07, 2024 | 412.08M |
| March 06, 2024 | 342.41M |
| March 05, 2024 | 352.96M |
| March 04, 2024 | 370.74M |
| March 01, 2024 | 357.09M |
| February 29, 2024 | 314.71M |
| February 28, 2024 | 284.73M |
| February 27, 2024 | 264.78M |
| February 26, 2024 | 290.11M |
| February 23, 2024 | 261.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-40.47M
Minimum
May 12 2022
703.09M
Maximum
Sep 02 2020
137.88M
Average
47.11M
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 7.819M |
| Perspective Therapeutics Inc | 1.055B |
| Protalix BioTherapeutics Inc | 58.97M |
| Electromed Inc | 148.76M |
| Armata Pharmaceuticals Inc | 158.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.021M |
| Total Expenses (Quarterly) | 10.10M |
| EPS Diluted (Quarterly) | -1.79 |
| Earnings Yield | -26.70% |
| Normalized Earnings Yield | -31.55 |